{"id":73296,"date":"2026-04-17T15:10:51","date_gmt":"2026-04-17T09:40:51","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=73296"},"modified":"2026-04-17T15:10:53","modified_gmt":"2026-04-17T09:40:53","slug":"nureca-q4-results-2026-date-revenue-pat-amp-analyst-outlook","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/nureca-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/","title":{"rendered":"Nureca Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook"},"content":{"rendered":"<p>Nureca (NSE: NURECA) is preparing to announce its Q4 FY26 financial results for the quarter ended March 31, 2026. With Nureca trading at Rs 320 \u2014 against a 52-week high of Rs 610 and a 1-year return of -42% \u2014 the Q4 FY26 results will be a pivotal event for investors in the Consumer Health sector.<\/p><p>Analyst estimates for Q4 FY26 revenue stand at Rs 90\u2013105 Cr, with PAT expectations of Rs 8\u201312 Cr and margin projections of EBITDA 10\u201313%. This article covers the Nureca Q4 results 2026 date, detailed earnings estimates, five key performance factors, five risks to monitor, analyst ratings and price targets, and answers to the most commonly searched investor questions.<\/p><p>Get free investment predictions and live Q4 result alerts on <a href=\"https:\/\/univest.in\/user\/log-in\">Univest<\/a>.<\/p><div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/nureca-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Nureca_Q4_Results_2026_Date\" title=\"Nureca Q4 Results 2026 Date\">Nureca Q4 Results 2026 Date<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/nureca-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Why_This_Quarter_Matters\" title=\"Why This Quarter Matters\">Why This Quarter Matters<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/nureca-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Nureca_Q4_FY26_Earnings_Estimates\" title=\"Nureca Q4 FY26 Earnings Estimates\">Nureca Q4 FY26 Earnings Estimates<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/nureca-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#5_Key_Factors_That_Will_Drive_Nureca_Q4_FY26_Performance\" title=\"5 Key Factors That Will Drive Nureca Q4 FY26 Performance\">5 Key Factors That Will Drive Nureca Q4 FY26 Performance<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/nureca-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#D2C_Health_Device_Recovery\" title=\"D2C Health Device Recovery\">D2C Health Device Recovery<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/nureca-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Offline_Distribution_Expansion\" title=\"Offline Distribution Expansion\">Offline Distribution Expansion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/nureca-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#International_Markets_Export_Push\" title=\"International Markets &amp; Export Push\">International Markets &amp; Export Push<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/nureca-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Operating_Leverage_from_Fixed_Cost_Base\" title=\"Operating Leverage from Fixed Cost Base\">Operating Leverage from Fixed Cost Base<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/nureca-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#New_Product_Launches_and_Category_Expansion\" title=\"New Product Launches and Category Expansion\">New Product Launches and Category Expansion<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/nureca-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#5_Risks_to_Watch_in_Nureca_Q4_FY26\" title=\"5 Risks to Watch in Nureca Q4 FY26\">5 Risks to Watch in Nureca Q4 FY26<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/nureca-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#D2C_Market_Competition\" title=\"D2C Market Competition\">D2C Market Competition<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/nureca-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Post-Pandemic_Demand_Normalisation\" title=\"Post-Pandemic Demand Normalisation\">Post-Pandemic Demand Normalisation<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/nureca-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Supply_Chain_and_Import_Dependency\" title=\"Supply Chain and Import Dependency\">Supply Chain and Import Dependency<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/nureca-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Platform_Concentration_Risk\" title=\"Platform Concentration Risk\">Platform Concentration Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/nureca-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Working_Capital_and_Inventory_Build\" title=\"Working Capital and Inventory Build\">Working Capital and Inventory Build<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/nureca-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Nureca_Share_Price_and_Analyst_Ratings\" title=\"Nureca Share Price and Analyst Ratings\">Nureca Share Price and Analyst Ratings<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/nureca-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/nureca-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/nureca-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#What_is_the_Nureca_Q4_results_2026_date\" title=\"What is the Nureca Q4 results 2026 date?\">What is the Nureca Q4 results 2026 date?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/nureca-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#What_is_the_Nureca_Q4_FY26_PAT_estimate\" title=\"What is the Nureca Q4 FY26 PAT estimate?\">What is the Nureca Q4 FY26 PAT estimate?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/nureca-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#What_is_Nurecas_share_price_ahead_of_Q4_results\" title=\"What is Nureca&#8217;s share price ahead of Q4 results?\">What is Nureca&#8217;s share price ahead of Q4 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/nureca-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Will_Nureca_declare_a_dividend_in_Q4_2026\" title=\"Will Nureca declare a dividend in Q4 2026?\">Will Nureca declare a dividend in Q4 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/nureca-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Which_analysts_have_a_Buy_rating_on_Nureca\" title=\"Which analysts have a Buy rating on Nureca?\">Which analysts have a Buy rating on Nureca?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/univest.in\/blogs-2\/nureca-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#What_were_Nureca_Q3_FY26_results\" title=\"What were Nureca Q3 FY26 results?\">What were Nureca Q3 FY26 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/univest.in\/blogs-2\/nureca-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#When_do_Infosys_and_TCS_announce_Q4_results_2026\" title=\"When do Infosys and TCS announce Q4 results 2026?\">When do Infosys and TCS announce Q4 results 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/univest.in\/blogs-2\/nureca-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Is_Nureca_a_good_investment_ahead_of_Q4_results\" title=\"Is Nureca a good investment ahead of Q4 results?\">Is Nureca a good investment ahead of Q4 results?<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/univest.in\/blogs-2\/nureca-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Recent_Article\" title=\"Recent Article\">Recent Article<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Nureca_Q4_Results_2026_Date\"><\/span><strong>Nureca Q4 Results 2026 Date<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Company<\/strong><\/td><td><strong>Q4 FY26 Results Date<\/strong><\/td><td><strong>Sector<\/strong><\/td><\/tr><tr><td><a href=\"https:\/\/univest.in\/blogs\/tcs-q4-results-2026-date-preview\">TCS<\/a><\/td><td>April 9, 2026<\/td><td>IT Services<\/td><\/tr><tr><td><a href=\"https:\/\/univest.in\/blogs\/infosys-q4-results-2026-date-preview\">Infosys<\/a><\/td><td>April 23, 2026<\/td><td>IT Services<\/td><\/tr><tr><td>Nureca<\/td><td>May 2026 (Expected)<\/td><td>See article<\/td><\/tr><\/tbody><\/table><\/figure><p>Nureca has scheduled its Q4 FY26 results for May 2026 (Expected). The board of directors will meet on this date to approve the audited financial statements for the quarter ended March 31, 2026, and to consider a final dividend recommendation. At a current market price of Rs 320, investors and analysts are closely watching this announcement for revenue growth confirmation and FY27 guidance.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Why_This_Quarter_Matters\"><\/span><strong>Why This Quarter Matters<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Q4 is the final quarter of the financial year \u2014 it determines full-year FY26 performance, sets the FY27 estimate base, and triggers final dividend announcements. For Nureca, which operates in the Consumer Health sector, Q4 FY26 will reveal whether momentum from earlier quarters has been sustained and whether management&#8217;s strategic initiatives have translated into financial outcomes.<\/p><p>At a 1-year return of -42%, this quarter&#8217;s results and FY27 guidance will be critical in determining whether the stock can begin a recovery. Investors will watch for order pipeline updates, margin trajectory, and capex guidance \u2014 any positive surprise on multiple parameters could drive a meaningful post-results re-rating.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Nureca_Q4_FY26_Earnings_Estimates\"><\/span><strong>Nureca Q4 FY26 Earnings Estimates<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><figure class=\"wp-block-image size-large\"><img fetchpriority=\"high\" decoding=\"async\" width=\"1024\" height=\"536\" src=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17151022\/Nureca-Q4-FY26-Estimates-1024x536.jpg\" alt=\"Nureca Q4 FY26 Earnings Estimates\" class=\"wp-image-73303\" srcset=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17151022\/Nureca-Q4-FY26-Estimates-1024x536.jpg 1024w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17151022\/Nureca-Q4-FY26-Estimates-300x157.jpg 300w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17151022\/Nureca-Q4-FY26-Estimates-768x402.jpg 768w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17151022\/Nureca-Q4-FY26-Estimates-900x471.jpg 900w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17151022\/Nureca-Q4-FY26-Estimates-600x314.jpg 600w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17151022\/Nureca-Q4-FY26-Estimates-150x79.jpg 150w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17151022\/Nureca-Q4-FY26-Estimates.jpg 1200w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure><p>Nureca Q4 FY26 Analyst Estimates at a Glance | Source: MOFSL, YES Securities, JM Financial<\/p><p>Access premium SEBI-registered research on <a href=\"https:\/\/univest.in\/user\/log-in\">Univest<\/a>.<\/p><p>Analysts covering Nureca have published Q4 FY26 estimates based on Q3 FY26 actuals, sector trends, and company-specific catalysts. Consensus estimates point to revenue of Rs 90\u2013105 Cr, PAT of Rs 8\u201312 Cr, and margins of EBITDA 10\u201313%. These projections reflect both the seasonal strength of Q4 and ongoing structural improvements in Nureca&#8217;s business model.<\/p><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Metric<\/strong><\/td><td><strong>Q3 FY26 Actual<\/strong><\/td><td><strong>Q4 FY26 Estimate<\/strong><\/td><\/tr><tr><td>Revenue<\/td><td>Rs 82 Cr<\/td><td>Rs 90\u2013105 Cr<\/td><\/tr><tr><td>PAT<\/td><td>Rs 7.2 Cr<\/td><td>Rs 8\u201312 Cr<\/td><\/tr><tr><td>Margin<\/td><td>EBITDA 10.5%<\/td><td>EBITDA 10\u201313%<\/td><\/tr><tr><td>Growth Driver<\/td><td>Base quarter<\/td><td>Growth catalyst<\/td><\/tr><tr><td>Dividend<\/td><td>Nil<\/td><td>Nil expected<\/td><\/tr><\/tbody><\/table><\/figure><p>Beyond headline numbers, investors will closely monitor FY27 guidance commentary, order book evolution, working capital trends, and any one-time items that could inflate or suppress reported PAT. A clean recurring profit print is more positively received by the market than results driven by non-operational gains.<\/p><p>Screen <a href=\"https:\/\/univest.in\/screeners\">Nureca<\/a> fundamentals on <a href=\"https:\/\/univest.in\/screeners\">Univest Screener<\/a>.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"5_Key_Factors_That_Will_Drive_Nureca_Q4_FY26_Performance\"><\/span><strong>5 Key Factors That Will Drive Nureca Q4 FY26 Performance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"D2C_Health_Device_Recovery\"><\/span><strong>D2C Health Device Recovery<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Nureca&#8217;s D2C portfolio of health monitoring devices \u2014 including blood pressure monitors, glucometers, and thermometers \u2014 saw strong pandemic-era demand which has since normalised. Q4 FY26 will reveal whether the company has successfully repositioned its sales channels through offline expansion and institutional tie-ups. Management has been focused on building a premium brand perception in the health-tech space, which could drive ASP (average selling price) improvement and better gross margins in the coming quarters.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Offline_Distribution_Expansion\"><\/span><strong>Offline Distribution Expansion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Nureca has been aggressively expanding its offline retail presence beyond its initial online-first model. Partnerships with modern trade chains and pharmacy networks are expected to contribute meaningfully to Q4 FY26 revenue. Offline channels typically command better margins due to reduced platform fee dependency. Any evidence of accelerating offline revenue share would be viewed as a strong positive structural signal by analysts.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"International_Markets_Export_Push\"><\/span><strong>International Markets &amp; Export Push<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Nureca has been exploring exports to Southeast Asia and the Middle East as part of its medium-term growth strategy. Q4 results will provide an update on progress in these new geographies. Export revenues, even if small in absolute terms, carry strong margin potential given the premiumisation of health devices in emerging markets and reduced domestic competitive pressure in international channels.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Operating_Leverage_from_Fixed_Cost_Base\"><\/span><strong>Operating Leverage from Fixed Cost Base<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>As revenue scales, Nureca&#8217;s fixed cost base \u2014 including its warehousing, tech platform, and brand spend \u2014 provides operating leverage potential. Q4 FY26 revenue at the upper end of the Rs 90\u2013105 Cr estimate range would meaningfully improve EBITDA margins beyond the 13% level and demonstrate the scalability of the business model for investors looking at the FY27 growth trajectory.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"New_Product_Launches_and_Category_Expansion\"><\/span><strong>New Product Launches and Category Expansion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Nureca has been expanding into adjacent health categories including fitness trackers, smart scales, and pain management devices. Q4 FY26 will reflect the initial revenue contribution from newer SKUs launched in H2 FY26. Successful category expansion reduces dependence on any single product line and improves the overall revenue quality and repeatability of the business.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"5_Risks_to_Watch_in_Nureca_Q4_FY26\"><\/span><strong>5 Risks to Watch in Nureca Q4 FY26<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"D2C_Market_Competition\"><\/span><strong>D2C Market Competition<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The online health device market in India has seen intensifying competition from both global brands (Omron, Beurer) and domestic entrants. Margin pressure from promotional spend and price competition could weigh on Nureca&#8217;s Q4 FY26 gross margins despite revenue growth.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Post-Pandemic_Demand_Normalisation\"><\/span><strong>Post-Pandemic Demand Normalisation<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Health device demand surged during COVID-19 but has moderated post-pandemic. Nureca must demonstrate it can grow revenues in a normalised environment, which may require higher marketing investment and channel discounts that compress margins.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Supply_Chain_and_Import_Dependency\"><\/span><strong>Supply Chain and Import Dependency<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Nureca sources components primarily from China and imports finished devices. Rupee depreciation or US-China trade tensions causing supply chain disruptions could increase input costs and hurt gross margins in Q4 FY26.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Platform_Concentration_Risk\"><\/span><strong>Platform Concentration Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>A significant portion of Nureca&#8217;s revenues historically came from Amazon and Flipkart. Platform fee increases or algorithmic changes affecting product visibility could impact revenues and margins in a single quarter significantly.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Working_Capital_and_Inventory_Build\"><\/span><strong>Working Capital and Inventory Build<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Health device companies face seasonal inventory build before high-demand periods. If Q4 sell-through is below expectations, inventory write-downs or elevated working capital could pressure free cash flow and balance sheet quality.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Nureca_Share_Price_and_Analyst_Ratings\"><\/span><strong>Nureca Share Price and Analyst Ratings<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"536\" src=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17150810\/image-1060-1024x536.jpeg\" alt=\"Nureca Share Price and Analyst Ratings\" class=\"wp-image-73298\" srcset=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17150810\/image-1060-1024x536.jpeg 1024w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17150810\/image-1060-300x157.jpeg 300w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17150810\/image-1060-768x402.jpeg 768w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17150810\/image-1060-900x471.jpeg 900w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17150810\/image-1060-600x314.jpeg 600w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17150810\/image-1060-150x79.jpeg 150w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17150810\/image-1060.jpeg 1200w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure><p>Nureca Share Price &amp; Analyst Ratings | Source: NSE\/BSE, Broker Notes<\/p><p>Nureca is trading at Rs 320 as of early April 2026, against a 52-week high of Rs 610 and 52-week low of Rs 275. Market cap stands at Rs 960 Cr. The 1-year return of -42% reflects sector headwinds alongside company-specific factors. Analyst price targets range from the conservative to the optimistic, reflecting differing views on the pace of business recovery and margin expansion.<\/p><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Brokerage<\/strong><\/td><td><strong>Rating<\/strong><\/td><td><strong>Target Price<\/strong><\/td><td><strong>Thesis<\/strong><\/td><\/tr><tr><td>MOFSL<\/td><td>Neutral<\/td><td>Rs 380<\/td><td>Margin recovery; watch D2C<\/td><\/tr><tr><td>YES Securities<\/td><td>Buy<\/td><td>Rs 450<\/td><td>Health device upcycle<\/td><\/tr><tr><td>JM Financial<\/td><td>Neutral<\/td><td>Rs 370<\/td><td>Channel expansion key<\/td><\/tr><\/tbody><\/table><\/figure><p>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Nureca&#8217;s live price and receive real-time Q4 result alerts.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Nureca&#8217;s Q4 FY26 results will test whether the company&#8217;s shift toward offline channels and international markets is gaining traction. At Rs 320, the stock is trading significantly below its 52-week high of Rs 610, reflecting investor concern about post-pandemic demand normalisation. A revenue print at the upper end of Rs 90\u2013105 Cr with improving EBITDA margins would likely trigger a re-rating. Investors should watch closely for FY27 guidance on new product launches and the offline channel ramp. Consult a SEBI-registered advisor before investing.<\/p><p>This content is published by Univest, a SEBI-registered research and advisory platform. All analyst estimates and price targets cited are from publicly available broker notes. Past performance is not indicative of future results. Investors should conduct independent due diligence before making any investment decisions.<\/p><p>For more Q4 FY26 previews across IT, banking, auto, pharma, and cement sectors, visit <a href=\"https:\/\/univest.in\/blogs\">Univest Blogs<\/a>.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_is_the_Nureca_Q4_results_2026_date\"><\/span><strong>What is the Nureca Q4 results 2026 date?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Nureca Q4 FY26 results are scheduled for May 2026 (Expected). The board of directors will meet on this date to approve the audited financial statements and consider a dividend recommendation for FY26.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_is_the_Nureca_Q4_FY26_PAT_estimate\"><\/span><strong>What is the Nureca Q4 FY26 PAT estimate?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Analysts estimate Nureca Q4 FY26 net profit (PAT) in the range of Rs 8\u201312 Cr. This estimate is based on revenue assumptions of Rs 90\u2013105 Cr and a margin of EBITDA 10\u201313%. Actual results may differ from these consensus estimates.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_is_Nurecas_share_price_ahead_of_Q4_results\"><\/span><strong>What is Nureca&#8217;s share price ahead of Q4 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Nureca shares are trading at approximately Rs 320 as of early April 2026. The 52-week high is Rs 610 and the 52-week low is Rs 275. The one-year return is -42% and the market cap stands at Rs 960 Cr.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Will_Nureca_declare_a_dividend_in_Q4_2026\"><\/span><strong>Will Nureca declare a dividend in Q4 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Nureca is expected to consider a dividend of Nil expected at the Q4 FY26 board meeting on May 2026 (Expected). The quantum signals management&#8217;s confidence in free cash flow generation for FY26.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Which_analysts_have_a_Buy_rating_on_Nureca\"><\/span><strong>Which analysts have a Buy rating on Nureca?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>YES Securities (target Rs 450) have positive ratings on Nureca ahead of Q4 FY26 results.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_were_Nureca_Q3_FY26_results\"><\/span><strong>What were Nureca Q3 FY26 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>In Q3 FY26, Nureca reported revenue of Rs 82 Cr and PAT of Rs 7.2 Cr, with margins at EBITDA 10.5%. These numbers provided the base for Q4 FY26 estimates and analyst coverage updates.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"When_do_Infosys_and_TCS_announce_Q4_results_2026\"><\/span><strong>When do Infosys and TCS announce Q4 results 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>TCS announced Q4 FY26 results on April 9, 2026. See the full <a href=\"https:\/\/univest.in\/blogs\/tcs-q4-results-2026-date-preview\">TCS Q4 Results 2026<\/a> preview. <a href=\"https:\/\/univest.in\/blogs\/infosys-q4-results-2026-date-preview\">Infosys<\/a> announced Q4 FY26 results on April 23, 2026.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Is_Nureca_a_good_investment_ahead_of_Q4_results\"><\/span><strong>Is Nureca a good investment ahead of Q4 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Nureca at Rs 320 offers a risk-reward that depends on Q4 execution and FY27 guidance. Investors should review the analyst estimates, monitor the results announcement, and consult a SEBI-registered advisor before making investment decisions. Past performance is not indicative of future results.<\/p><p>Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All financial data and analyst estimates are sourced from publicly available information including NSE\/BSE filings and company investor relations pages. Verify all numbers before investing. Consult a SEBI-registered advisor before making investment decisions.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Recent_Article\"><\/span><strong>Recent Article<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><a href=\"https:\/\/univest.in\/blogs\/motisons-jewellers-q4-results-2026\">Motisons Jewellers Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/motilal-oswal-financial-services-q4-results-2026\">Motilal Oswal Financial Services Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/moschip-technologies-q4-results-2026\">Moschip Technologies Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/morepen-laboratories-q4-results-2026\">Morepen Laboratories Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/morarjee-textiles-q4-results-2026\">Morarjee Textiles Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p><p><\/p>","protected":false},"excerpt":{"rendered":"<p>Nureca (NSE: NURECA) is preparing to announce its Q4 FY26 financial results for the quarter ended March 31, 2026. With Nureca trading at Rs 320 \u2014 against a 52-week high of Rs 610 and a 1-year return of -42% \u2014 the Q4 FY26 results will be a pivotal event for investors in the Consumer Health<\/p>\n","protected":false},"author":27,"featured_media":73299,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802,3862],"class_list":["post-73296","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news","tag-q4-results-expectations"],"metadata":{"_edit_lock":["1776418919:27"],"_last_editor_used_jetpack":["block-editor"],"rank_math_internal_links_processed":["1"],"amazonS3_cache":["a:8:{s:63:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/image-1060.jpeg\";a:2:{s:2:\"id\";i:73298;s:11:\"source_type\";s:13:\"media-library\";}s:72:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/image-1060-1024x536.jpeg\";a:2:{s:2:\"id\";i:73298;s:11:\"source_type\";s:13:\"media-library\";}s:95:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17150810\/image-1060.jpeg\";a:2:{s:2:\"id\";i:73298;s:11:\"source_type\";s:13:\"media-library\";}s:104:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17150810\/image-1060-1024x536.jpeg\";a:2:{s:2:\"id\";i:73298;s:11:\"source_type\";s:13:\"media-library\";}s:76:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/Nureca-Q4-FY26-Estimates.jpg\";a:2:{s:2:\"id\";i:73303;s:11:\"source_type\";s:13:\"media-library\";}s:85:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/Nureca-Q4-FY26-Estimates-1024x536.jpg\";a:2:{s:2:\"id\";i:73303;s:11:\"source_type\";s:13:\"media-library\";}s:108:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17151022\/Nureca-Q4-FY26-Estimates.jpg\";a:2:{s:2:\"id\";i:73303;s:11:\"source_type\";s:13:\"media-library\";}s:117:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17151022\/Nureca-Q4-FY26-Estimates-1024x536.jpg\";a:2:{s:2:\"id\";i:73303;s:11:\"source_type\";s:13:\"media-library\";}}"],"rank_math_primary_category":["842"],"rank_math_seo_score":["83"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"rank_math_title":["Nureca Q4 Results 2026: Date, Revenue &amp; PAT Estimates"],"rank_math_description":[" Nureca Q4 FY26 results expected May 2026. Revenue estimate Rs 90\u2013105 Cr, PAT Rs 8\u201312 Cr. Full preview with analyst targets, key factors and share price outlook.\n"],"rank_math_focus_keyword":["Nureca"],"_thumbnail_id":["73299"],"_edit_last":["27"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["8398"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17150832\/Nureca-Q4-Results-2026.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/73296","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/27"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=73296"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/73296\/revisions"}],"predecessor-version":[{"id":73304,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/73296\/revisions\/73304"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/73299"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=73296"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=73296"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=73296"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}